AAV Capsid Serotyping via LC-MS Mass Fingerprinting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and characterizing viral capsid serotypes, such as those of adeno-associated virus (AAV), are inadequate as they rely on non-specific techniques like SDS-PAGE banding patterns and antibody-based assays, which are time-consuming and provide limited sequence coverage.
Innovation Solution
The use of liquid chromatography/mass spectrometry (LC/MS) and liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) to specifically identify viral capsid serotypes by determining the masses of capsid proteins VP1, VP2, and VP3, allowing for the differentiation of various AAV serotypes and monitoring of capsid protein heterogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional molecular identification methods (PCR, RFLP) are used to identify rAAV products, then the transgene identity can be determined, but the AAV capsid serotype cannot be differentiated
Solution Approach 1:
The viral particle is segmented into its functional components: the transgene (nucleic acid) and the capsid protein. Different analytical methods are applied to each segment - molecular tools for transgene identification and mass spectrometry for capsid serotyping - thereby preserving both types of information without cross-contamination of analytical approaches
Solution Approach 2:
The mass spectrometry method serves multiple functions: it identifies the capsid serotype through mass fingerprinting, detects capsid protein heterogeneity, and can potentially identify post-translational modifications. This single technique replaces multiple specialized assays and provides comprehensive capsid characterization
2Ease of manufacture
If SDS-PAGE banding patterns or antibody-based ELISA are used for capsid serotype identification, then the analysis can be performed with simple equipment, but the results lack specificity to differentiate different AAV serotypes
Solution Approach 1:
The patent replaces mechanical/separation-based identification methods (SDS-PAGE banding patterns) and antibody-antigen binding methods (ELISA, Western blot) with mass spectrometry-based identification. This substitution uses physical measurement of mass-to-charge ratio rather than mechanical separation or biochemical binding, providing superior specificity through precise mass measurement of capsid proteins
Solution Approach 2:
The patent changes the measurement parameter from visual banding patterns or antibody reactivity to precise mass measurement. By measuring the mass-to-charge ratio of ions corresponding to capsid proteins, the method achieves serotype differentiation based on unique mass fingerprints rather than relying on non-specific patterns or antibody cross-reactivity
3Loss of information
If Gel-LC/MS/MS method is used for capsid serotype identification, then sequence coverage can be obtained, but the analysis requires multiple steps including SDS-PAGE, in-gel digestion, and LC/MS/MS taking multiple days
Solution Approach 1:
The patent extracts and eliminates the time-consuming intermediate steps from the analytical workflow. By removing the SDS-PAGE separation step and the in-gel digestion step, the method goes directly from viral particle preparation to mass spectrometry analysis, thereby reducing analysis time while maintaining sequence coverage capability
Solution Approach 2:
The patent performs preliminary denaturation of the viral capsid proteins to unfold them and expose peptide sequences for mass spectrometry analysis. This preliminary action prepares the proteins for direct analysis without requiring subsequent gel separation and in-gel digestion, achieving both time savings and adequate sequence coverage
4Quantity of substance
If non-specific identification methods are used, then the cost of equipment and reagents is low, but the accuracy and efficiency of viral capsid serotyping is insufficient to satisfy regulatory requirements
Solution Approach 1:
The patent replaces low-cost but non-specific methods with mass spectrometry technology that provides regulatory-compliant results. The substitution justifies the higher instrument cost through superior measurement capability, data quality, and ability to provide definitive serotype identification and heterogeneity assessment required by regulatory authorities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enhances the accuracy and efficiency of viral capsid serotyping, satisfying regulatory requirements and enabling better characterization of viral particles for gene therapy applications, while also allowing for the study of post-translational modifications' impact on transfection potency and protein trafficking.
Implementation Method 1
liquid chromatography/mass spectrometry (LC/MS)
Implementation Method 2
mass spectrometry (LC/MS) or liquid chromatography/mass spectrometry-mass spectrometry (LC/MS/MS)
Data Source
AI summary
Provided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins.